JP2012505637A5 - - Google Patents

Info

Publication number

JP2012505637A5

JP2012505637A5 JP2011531313A JP2011531313A JP2012505637A5 JP 2012505637 A5 JP2012505637 A5 JP 2012505637A5 JP 2011531313 A JP2011531313 A JP 2011531313A JP 2011531313 A JP2011531313 A JP 2011531313A JP 2012505637 A5 JP2012505637 A5 JP 2012505637A5

Authority

JP

Japan

Prior art keywords

compound

angiopep

treat

subject

seq

Prior art date

2009-10-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 29
• 238000000034 method Methods 0.000 claims 12
• 108090000765 processed proteins & peptides Proteins 0.000 claims 9
• 229920001184 polypeptide Polymers 0.000 claims 8
• 102000004196 processed proteins & peptides Human genes 0.000 claims 8
• 108010011459 Exenatide Proteins 0.000 claims 7
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 7
• 229960001519 exenatide Drugs 0.000 claims 7
• 108010064942 Angiopep-2 Proteins 0.000 claims 4
• 150000001413 amino acids Chemical group 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 208000035475 disorder Diseases 0.000 claims 4
• 208000008589 Obesity Diseases 0.000 claims 3
• 230000000694 effects Effects 0.000 claims 3
• 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 3
• 235000020824 obesity Nutrition 0.000 claims 3
• 208000024827 Alzheimer disease Diseases 0.000 claims 2
• 206010010904 Convulsion Diseases 0.000 claims 2
• 208000032928 Dyslipidaemia Diseases 0.000 claims 2
• 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
• 208000018737 Parkinson disease Diseases 0.000 claims 2
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
• 239000008280 blood Substances 0.000 claims 2
• 210000004369 blood Anatomy 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 230000037406 food intake Effects 0.000 claims 2
• 235000012631 food intake Nutrition 0.000 claims 2
• 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
• 208000030159 metabolic disease Diseases 0.000 claims 2
• 208000010125 myocardial infarction Diseases 0.000 claims 2
• 230000004766 neurogenesis Effects 0.000 claims 2
• 102000039446 nucleic acids Human genes 0.000 claims 2
• 108020004707 nucleic acids Proteins 0.000 claims 2
• 150000007523 nucleic acids Chemical class 0.000 claims 2
• 230000002980 postoperative effect Effects 0.000 claims 2
• 150000003141 primary amines Chemical class 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• 210000000130 stem cell Anatomy 0.000 claims 2
• 208000011580 syndromic disease Diseases 0.000 claims 2
• 150000003573 thiols Chemical class 0.000 claims 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 230000002485 urinary effect Effects 0.000 claims 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
• 208000019901 Anxiety disease Diseases 0.000 claims 1
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
• 208000032841 Bulimia Diseases 0.000 claims 1
• 206010006550 Bulimia nervosa Diseases 0.000 claims 1
• 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
• 208000024172 Cardiovascular disease Diseases 0.000 claims 1
• 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
• 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
• 206010012735 Diarrhoea Diseases 0.000 claims 1
• 208000008279 Dumping Syndrome Diseases 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 206010019280 Heart failures Diseases 0.000 claims 1
• 208000023105 Huntington disease Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 208000004356 Hysteria Diseases 0.000 claims 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
• 206010022489 Insulin Resistance Diseases 0.000 claims 1
• 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
• 208000016285 Movement disease Diseases 0.000 claims 1
• 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
• 206010071323 Neuropsychiatric syndrome Diseases 0.000 claims 1
• 206010029333 Neurosis Diseases 0.000 claims 1
• 206010033307 Overweight Diseases 0.000 claims 1
• 206010033664 Panic attack Diseases 0.000 claims 1
• 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
• 208000028017 Psychotic disease Diseases 0.000 claims 1
• 206010037423 Pulmonary oedema Diseases 0.000 claims 1
• 208000001647 Renal Insufficiency Diseases 0.000 claims 1
• 206010038687 Respiratory distress Diseases 0.000 claims 1
• 230000002159 abnormal effect Effects 0.000 claims 1
• 239000002253 acid Substances 0.000 claims 1
• 230000016571 aggressive behavior Effects 0.000 claims 1
• 235000001014 amino acid Nutrition 0.000 claims 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
• 230000036506 anxiety Effects 0.000 claims 1
• 230000036528 appetite Effects 0.000 claims 1
• 235000019789 appetite Nutrition 0.000 claims 1
• 230000008499 blood brain barrier function Effects 0.000 claims 1
• 230000017531 blood circulation Effects 0.000 claims 1
• 230000036765 blood level Effects 0.000 claims 1
• 210000001218 blood-brain barrier Anatomy 0.000 claims 1
• 230000001925 catabolic effect Effects 0.000 claims 1
• 230000015556 catabolic process Effects 0.000 claims 1
• 230000007882 cirrhosis Effects 0.000 claims 1
• 208000019425 cirrhosis of liver Diseases 0.000 claims 1
• 208000012839 conversion disease Diseases 0.000 claims 1
• 235000018417 cysteine Nutrition 0.000 claims 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
• 238000006731 degradation reaction Methods 0.000 claims 1
• 230000001079 digestive effect Effects 0.000 claims 1
• 239000000539 dimer Substances 0.000 claims 1
• 230000002183 duodenal effect Effects 0.000 claims 1
• 230000004064 dysfunction Effects 0.000 claims 1
• 230000029142 excretion Effects 0.000 claims 1
• 239000012634 fragment Substances 0.000 claims 1
• 239000008103 glucose Substances 0.000 claims 1
• 230000002641 glycemic effect Effects 0.000 claims 1
• 201000001421 hyperglycemia Diseases 0.000 claims 1
• 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
• 238000001802 infusion Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 230000000297 inotrophic effect Effects 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 208000028867 ischemia Diseases 0.000 claims 1
• 208000017169 kidney disease Diseases 0.000 claims 1
• 201000006370 kidney failure Diseases 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 210000004165 myocardium Anatomy 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 208000015238 neurotic disease Diseases 0.000 claims 1
• 229960002748 norepinephrine Drugs 0.000 claims 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
• 235000016709 nutrition Nutrition 0.000 claims 1
• 230000035764 nutrition Effects 0.000 claims 1
• 210000000056 organ Anatomy 0.000 claims 1
• 208000019906 panic disease Diseases 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
• 229910052700 potassium Inorganic materials 0.000 claims 1
• 239000011591 potassium Substances 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 208000005333 pulmonary edema Diseases 0.000 claims 1
• 208000002815 pulmonary hypertension Diseases 0.000 claims 1
• 230000010410 reperfusion Effects 0.000 claims 1
• 230000004044 response Effects 0.000 claims 1
• 208000019116 sleep disease Diseases 0.000 claims 1
• 229910052708 sodium Inorganic materials 0.000 claims 1
• 239000011734 sodium Substances 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• 230000002194 synthesizing effect Effects 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
• 230000000451 tissue damage Effects 0.000 claims 1
• 231100000827 tissue damage Toxicity 0.000 claims 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
• 230000002861 ventricular Effects 0.000 claims 1